Skip to main navigation Skip to search Skip to main content

Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

  • Al B. Benson
  • , Michael I. D’Angelica
  • , Thomas Abrams
  • , Daniel E. Abbott
  • , Aijaz Ahmed
  • , Daniel A. Anaya
  • , Robert Anders
  • , Chandrakanth Are
  • , Melinda Bachini
  • , David Binder
  • , Mitesh Borad
  • , Christopher Bowlus
  • , Daniel Brown
  • , Adam Burgoyne
  • , Jason Castellanos
  • , Prabhleen Chahal
  • , Jordan Cloyd
  • , Anne M. Covey
  • , Evan S. Glazer
  • , William G. Hawkins
  • Renuka Iyer, Rojymon Jacob, Lawrence Jennings, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Sean Ronnekleiv-Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole McMillian, Ryan Schonfeld, Cindy Hochstetler
  • Northwestern University
  • Memorial Sloan-Kettering Cancer Center
  • Dana-Farber Cancer Institute
  • University of Wisconsin-Madison
  • Stanford University
  • University of South Florida
  • Johns Hopkins University
  • University of Nebraska Medical Center
  • Cholangiocarcinoma Foundation
  • University of Colorado Anschutz Medical Campus
  • Mayo Clinic
  • University of California at Davis
  • Vanderbilt University
  • University of California at San Diego
  • Case Western Reserve University
  • Ohio State University
  • University of Tennessee Health Science Center
  • Washington University St. Louis
  • Roswell Park Comprehensive Cancer Center
  • University of Alabama at Birmingham
  • University of California at San Francisco
  • University of Utah
  • University of Pennsylvania
  • Duke University
  • Fred Hutchinson Cancer Research Center
  • University of California at Los Angeles
  • University of Michigan, Ann Arbor
  • City of Hope National Medical Center
  • Yale University
  • Indiana University Bloomington
  • University of Texas MD Anderson Cancer Center
  • UT Southwestern Simmons Comprehensive Cancer Center
  • National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

205 Scopus citations

Abstract

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.

Original languageEnglish
Pages (from-to)694-704
Number of pages11
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume21
Issue number7
DOIs
StatePublished - Jul 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bile Duct Neoplasms
  • Bile Ducts, Intrahepatic
  • Biliary Tract Neoplasms/diagnosis
  • Cholangiocarcinoma/diagnosis
  • Gallbladder Neoplasms/diagnosis
  • Humans
  • Liver Neoplasms/diagnosis

Fingerprint

Dive into the research topics of 'Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this